Geron (GERN) Return on Sales (2010 - 2026)

Geron (GERN) posted Return on Sales of 0.0% for Q1 2026, down 131.56% sequentially from 0.0% in Q4 2025, and little changed YoY from 0.0% in Q1 2025.

Geron (GERN) Return on Sales (2010 - 2026) Analysis & Trends

Geron has reported Return on Sales for 17 years, with the latest figure at 0.0% in Q1 2026.

Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (down 1.0% YoY) and the FY2025 annual result came in at 1.29%, up 1042.0% from the prior year.
Return on Sales eased to 0.0% in Q1 2026 per GERN's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 2.37% in Q4 2023 and troughed at 18.17% in Q1 2023.
A 5-year average of 2.94% and a median of 0.76% in 2024 frame the typical range for Return on Sales.
The sharpest annual moves came in 2023 and 2024: Return on Sales sank 1568 bps in 2023, then surged 1635 bps in 2024.
Over 5 years, Return on Sales stood at 3.98% in 2022, then jumped by 160 bps to 2.37% in 2023, then tumbled by 100 bps to 0.01% in 2024, then slumped by 73 bps to 0.0% in 2025, then slumped by 132 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Geron	1.02 Mn	-299.83 Mn	-	0.00%

Download Data